Рет қаралды 1,498
The panelists, Daniel Heng, MD, MPH, FRCPC; Paul Nathan, MBBS, PhD, FRCP; Carlos H. Barrios, MD; Susannne Osanto, MD, PhD; and Nizar Tannir, MD, FACP, examine the application of prognostic and predictive factors in the selection of renal cell carcinoma (RCC) treatment.